Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Neurodegener Dis Manag
; 14(1): 11-20, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38318862
ABSTRACT
Aim:
This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex®) in the real-world setting in Germany. Patients &methods:
The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity.Results:
The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p < 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0-10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks.Conclusion:
Nabiximols is a useful therapeutic option for patients with MS spasticity.
People with multiple sclerosis (MS) spasticity experience a variety of symptoms and have individual expectations about a new treatment. This study investigated patients' perceptions about the effectiveness and tolerability of nabiximols oromucosal spray (Sativex®) when added to current medications for spasticity. Common treatment goals for patients (n = 51) were less pain, better walking and improved sleep. After 12 weeks of treatment, 62% of selected treatment goals were achieved 'as expected' or 'better than expected' and 65% of patients considered their spasticity to be 'much improved'. Meaningful improvements were recorded in spasticity-related symptoms of pain, sleep quality and bladder problems. Few side effects were reported. Nabiximols may be useful for MS patients with a poor response to usual spasticity medications.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Cannabidiol
/
Esclerosis Múltiple
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article